Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Califf Kicks Off Commissionership With Pledge To Counter Misinformation

Executive Summary

New FDA commissioner commitment to counter misinformation also appears to include pledge to ensure agency is driven by science-based decisions, not politics.

You may also be interested in...



US FDA’s Califf Says Publishing Complete Response Letters Could Help Fight Misinformation

But the commissioner also said proponents of releasing CRs may be making too much of the idea, because there are few CRs actually issued.

Did The US FDA Mix Politics And Science With Its Cancer Guidance Announcement?

Three new guidances were announced the morning of President Biden’s State of the Union address, but experts said the move did not equate with past White House pressure on agency decisions.

Dr. Califf Returns To US FDA: What To Do First?

Acting commissioner Janet Woodcock will remain at the agency and become principal deputy commissioner when Califf arrives.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS145725

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel